Jump to content
  1. Retroizzie

    Retroizzie

  2. KD3

    KD3

  3. immamymoulfub

    immamymoulfub

  • Similar Content

    • By RobertReny
      According to the new law passed by the Colorado government doctors can prescribe medical marijuana for patients suffering from cancer, HIV and AIDS, glaucoma, PTSD or other chronic medical condition that causes, nausea, severe pain, and seizures. The new law includes all medical conditions in which opioids could be recommended.
      https://www.myhealthyclick.com/colorado-passes-bill-that-allows-physicians-to-prescribe-medical-marijuana-rather-than-opioids/
       
       
    • By djziddi
      My mom has a strange type of glaucoma. She said it is Uvietis caused by glaucoma. And it has to do something about the pressure of her eye being too low or high. (Not sure which)
       
      And she asked her Dr. about medical marijuana and the doctor said that it might make it worse. Im not sure if her Dr is lieing to her or not..
      Anyone know about this?
    • By t-pain
      http://www.ncbi.nlm.nih.gov/pubmed/21414525
       
       
      CONCLUSIONS:

      Some cannabinoid agonists (WIN 55212-2, anandamide) have demonstrated, in experimental studies, to act as ideal drugs in the management of glaucoma, as they have been shown to have good tolerability after topical application, efficiently reduce intraocular pressure, and behave as neuroprotectors on retinal ganglion cells. Further studies as regards the safety and clinical assays must be carried out in order to examine the effectiveness of these drugs for the treatment of glaucoma in our daily clinical practice.
       
       
      aha, finally something tells you what they made eye drops from. of course this is a spanish>english machine translated scientific document , so there maybe errors and you should translate the page yourself before putting anything in your eye.
       
      Topical application of cannabinoids

      Due to the high lipid solubility, and the need to employ lipophilic products for proper dissolution, many vehicles have been tested, such as ethanol, dimethyl sulfoxide, polivinilpyrrolidone, Tween 80, Cremophor, emulphor, bovine serum albumin (BSA), 2-hydroxypropyl -β-ciclodextrino, and currently, it has been popularized Tocrisolve employing TM 67. the TM is a registered Tocrisolve preparation consisting of a vehicle designed for lipophilic compounds, such as cannabinoid and vanilloid agonists. The Tocrisolve TM consists of soybean oil in a ratio of 1:4 with water and is emulsified with the copolymer pluronic F68. Allows dissolve WIN 55212-2 to a concentration of 2%. On the other hand does not require the use of ethanol to promote your solution and has demonstrated a sustained ocular penetration agonist WIN 55212-2 dissolved therein applied topically after 68.

      The Δ9-THC, dissolved in mineral oil, was shown to reduce the intraocular pressure equal to or higher than that obtained by pilocarpine (52% reduction), with a more prolonged effect 38,68. This hypotensive effect has been reproduced in other studies with different cannabinoids ( Table 2 ).
       
       
      Topical application of Δ9-THC, CBN and CBD has been associated with mydriasis, conjunctival hyperemia, chemosis, severe cases of corneal opacification and neurotoxicity 70. Other ocular side effects associated with systemic administration routes are cannabinoids decrease in tear production, diplopia, accommodation disturbances, photophobia, nystagmus and blepharospasm 7,10,66,70.
       
      The use of new solvents such as Tocrisolve TM and the 2-hydroxypropyl-β-ciclodextrino allowed correct cannabinoies dissolving and preparing solutions suitable for ocular application. Although the results to date are promising for application in the field of glaucoma, more safety studies and clinical trials are still necessary to examine the usefulness of these compounds in the treatment of glaucoma in our clinic daily.
    • By t-pain
      http://www.sciencedaily.com/releases/2010/03/100324121002.htm
       
      this was on the radio today. not sure why it was talking about a contact lens from 2010, but maybe some news about it has updated.
       
      updated glaucoma research 5-2013
      http://www.revophth.com/content/c/40629
       
      Cannabinoids and glaucoma
      http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772142/
      mentions that THC and CBD decreases IOP
      (two different chemicals in the same plant can do the same medical benefit! how amazing is that?)
       
      reading scientific papers like this is so horrible when you read what they tried in the past. mixing medications with mineral oil so it would be more liquid. they report mineral oil causes eye irritation. thats why the mineral oil bottle has that warning label on it about not getting any in your eye, geniuses!
       
      researching the Glaucoma medicine Canasol made in jamaica
      http://www.cannabisculture.com/articles/59.html
      unfortunately, one of the doctors who worked on creating it passed away last year.
      http://jamaica-gleaner.com/gleaner/20120426/lead/lead5.html
       
       
      cant find any updated information on canasol.
       
      http://caribbean.scielo.org/scielo.php?script=sci_arttext&pid=S0043-31442012000600024
       
      http://jamaica-gleaner.com/gleaner/20130902/lead/lead6.html
      sept 2 - 2013 - School of marijuana - Research facility to be established
       
      http://jamaica-gleaner.com/latest/article.php?id=49710
      dec 4 2013 - Jamaica's first medical ganja company launched
       
      MediCanja will undertake pioneering research and product development using the medicinal compounds called the CBDs – the non-psychoactive compounds in ganja.
       
       
    • By t-pain
      who says marijuana does not work to reduce IOP in glaucoma?
       
      http://www.aosonline.org/xactions/2002/1545-6110_v100_p215.pdf
       
       
      even orally:
       
      This uncontrolled, unmasked, nonrandomized, prospec-tive study does not permit definitive conclusions about the
      efficacy or toxicity of cannabinoids in the treatment of
      glaucoma. There is an impression from this study that
      treatment with oral THC lowered IOP in this group of
      patients with end-stage open-angle glaucoma, but the
      development of tolerance and the coexistence of signifi-cant systemic toxicity limited the potential usefulness of
      this treatment. It was particularly impressive to the inves-tigators that throughout the study there was no observed
      tendency for either the physicians or the patients to abuse
      their access to cannabinoid derivatives. Furthermore, both
      the patients and ophthalmologists greatly appreciated the
      opportunity to participate in a study that gave them legal
      access to cannabinoids as a last-resort treatment for end-stage glaucoma unresponsive to conventional treatments.
       
      i do not understand why they talk about limited usefulness, the conventional medications had failed in these test subjects. it has tremendous usefulness for subjects where other medications do not work.
       
      i do not understand why they talk about toxicity to oral thc.
       
       
       
      All subjects experienced side effects during their
      treatment with THC during this study (Table III). The
      most commonly described toxic effects were dry mouth,
      sleepiness, dizziness, depression, and confusion; these
      effects were the same as those reported by other investi-gators.
      18,19Although many of the side effects were consid-ered mild and were of little concern to subjects, other effects were very significant.
×
×
  • Create New...